Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Jessica WuYanjun ChenLindsey HagemanLiton FranciscoEmily C NessMariel ParmanMichelle KungJames A WatsonDaniel J WeisdorfDavid S SnyderPhilip B McGlaveStephen J FormanMukta AroraSaro H ArmenianRavi BhatiaSmita BhatiaPublished in: Cancer (2019)
The similar late mortality experienced by patients with CML who undergo transplantation with or without pre-BMT TKIs suggests that allogeneic BMT can be considered in the context of TKI intolerance or nonadherence. The prevention of post-BMT non-CML-related mortality could favorably affect long-term survival.